REGULATORY

PMDA’s New Mid-Term Plan to Push Pediatric, Orphan Drug Development to Counter Losses

October 23, 2023

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

The Pharmaceuticals and Medical Devices Agency’s (PMDA) new mid-term plan starting next April is expected to embrace numerous measures to stamp out drug losses including active support for the development of pediatric and orphan medicines, according to its outline. The…

To read the full story

PMDA Looks to Rev Up Pediatric and Orphan Drug Initiatives in Next 5-Year Plan: Chief
March 11, 2024
PMDA Sets 6-Month Target for All SaMD Products under Priority Review
January 23, 2024

REGULATORY

MHLW to Add Company-Driven Route to “Specific-Use Drug” Designations
December 16, 2025
MHLW Council Determines 3 “Drug Loss” Products as High-Need, to Seek Development
December 16, 2025
LDP Biosimilar Group Submits Request to Finance Minister, Seeks Continued Support
December 16, 2025
LDP’s Patch League Urges Finance Minister to Continue Coverage, Support Prices
December 16, 2025
Chuikyo Backs Draft FY2026 Pricing Reform Outline, Rejects Key Industry Requests
December 15, 2025

Chuikyo Debate on FY2026 Drug Pricing Reform

Pharma Renews Call to Scrap “Spillover,” “Huge-Seller” Rules as FY2026 Talks Enter Final Stretch

By Ken Yoshino

Japan’s drug pricing panel held its final round of industry hearings on December 10 as it heads toward the FY2026…

COMMENTARY

FY2026 Reform Debate for Drug Pricing Nears the Finish Line, Balance Needed

By Takashi Ebisawa

Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…

COLUMN

AI in HR: Navigating the Ethical Minefield

By Philip Carrigan

Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…